JPWO2020256096A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020256096A5 JPWO2020256096A5 JP2021526910A JP2021526910A JPWO2020256096A5 JP WO2020256096 A5 JPWO2020256096 A5 JP WO2020256096A5 JP 2021526910 A JP2021526910 A JP 2021526910A JP 2021526910 A JP2021526910 A JP 2021526910A JP WO2020256096 A5 JPWO2020256096 A5 JP WO2020256096A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- day
- amino
- cancer
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 34
- 229940124597 therapeutic agent Drugs 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 5
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 claims 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- YJBAUTPCBIGXHL-UHFFFAOYSA-N 1-phenyl-4,5-dihydroimidazole Chemical compound C1=NCCN1C1=CC=CC=C1 YJBAUTPCBIGXHL-UHFFFAOYSA-N 0.000 claims 27
- -1 Oxazine-2-yl Chemical group 0.000 claims 16
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 5
- 201000005202 lung cancer Diseases 0.000 claims 5
- 208000020816 lung neoplasm Diseases 0.000 claims 5
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 3
- 206010061424 Anal cancer Diseases 0.000 claims 2
- 208000007860 Anus Neoplasms Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 201000011165 anus cancer Diseases 0.000 claims 2
- 201000007455 central nervous system cancer Diseases 0.000 claims 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 210000004392 genitalia Anatomy 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 description 10
- 229940125782 compound 2 Drugs 0.000 description 9
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019115496 | 2019-06-21 | ||
| JP2019115496 | 2019-06-21 | ||
| PCT/JP2020/024113 WO2020256096A1 (ja) | 2019-06-21 | 2020-06-19 | 悪性腫瘍の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020256096A1 JPWO2020256096A1 (https=) | 2020-12-24 |
| JPWO2020256096A5 true JPWO2020256096A5 (https=) | 2022-03-16 |
| JP7574184B2 JP7574184B2 (ja) | 2024-10-28 |
Family
ID=74040503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526910A Active JP7574184B2 (ja) | 2019-06-21 | 2020-06-19 | 悪性腫瘍の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220354858A1 (https=) |
| EP (1) | EP3988175A4 (https=) |
| JP (1) | JP7574184B2 (https=) |
| KR (1) | KR20220024821A (https=) |
| AU (1) | AU2020297166A1 (https=) |
| MA (1) | MA56549A (https=) |
| TW (1) | TWI856115B (https=) |
| WO (1) | WO2020256096A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| EP4284378A4 (en) * | 2021-02-01 | 2024-12-25 | Taiho Pharmaceutical Co., Ltd. | Ptentreating cancer in patient with pten inactivating mutation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101658274B1 (ko) | 2011-04-06 | 2016-09-22 | 다이호야쿠힌고교 가부시키가이샤 | 신규 이미다조 옥사진 화합물 또는 그의 염 |
| DK2657233T3 (da) | 2012-01-19 | 2014-09-22 | Taiho Pharmaceutical Co Ltd | 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf |
| NO2868660T3 (https=) * | 2012-07-02 | 2018-05-26 | ||
| JP6289459B2 (ja) | 2013-06-20 | 2018-03-07 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| CN111943962A (zh) * | 2015-02-27 | 2020-11-17 | 大鹏药品工业株式会社 | 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
| EP3424505A4 (en) * | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP4093406A4 (en) * | 2020-01-24 | 2024-02-28 | Taiho Pharmaceutical Co., Ltd. | IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER |
| EP4284378A4 (en) * | 2021-02-01 | 2024-12-25 | Taiho Pharmaceutical Co., Ltd. | Ptentreating cancer in patient with pten inactivating mutation |
-
2020
- 2020-06-19 KR KR1020227002122A patent/KR20220024821A/ko not_active Withdrawn
- 2020-06-19 AU AU2020297166A patent/AU2020297166A1/en not_active Abandoned
- 2020-06-19 TW TW109120904A patent/TWI856115B/zh active
- 2020-06-19 EP EP20827927.3A patent/EP3988175A4/en active Pending
- 2020-06-19 WO PCT/JP2020/024113 patent/WO2020256096A1/ja not_active Ceased
- 2020-06-19 JP JP2021526910A patent/JP7574184B2/ja active Active
- 2020-06-19 US US17/620,419 patent/US20220354858A1/en active Pending
- 2020-06-19 MA MA056549A patent/MA56549A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020256096A5 (https=) | ||
| AU2014317119B2 (en) | Combination of a MEK inhibitor and an ERK inhibitor for use in treatment of hyperproliferative diseases | |
| Overgaard | Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors | |
| RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
| Ajani et al. | A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma | |
| MX2011000440A (es) | Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek. | |
| JPH10279482A (ja) | ピリミジン誘導体の単独で又は他の治療方法と組み合わせた癌の予防のための使用 | |
| EP3042652B1 (en) | Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament | |
| RU2009127351A (ru) | Комбинации антифолатного агента в лечении рака | |
| CN106317056A (zh) | 吡唑并嘧啶衍生物、其制备方法及其治疗用途 | |
| TW201919612A (zh) | 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合 | |
| JP2002363102A5 (https=) | ||
| AU2010200433A1 (en) | Combinations comprising a selective cyclooxygenase-2 inhibitor | |
| JP2009506054A5 (https=) | ||
| ITRM940328A1 (it) | Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario. - | |
| CN113056272A (zh) | 新的喹唑啉egfr抑制剂 | |
| US10702494B2 (en) | Method for cancer treatment | |
| JP2024546605A (ja) | がんを治療するための併用療法の使用 | |
| Wang et al. | Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control | |
| US20220125769A1 (en) | Estrogen receptor modulators for treating mutants | |
| JP2002540148A (ja) | テモゾロミドを用いる改善された癌処置 | |
| JP2022552975A (ja) | 関節リウマチを予防及び／又は治療するためのニコチンアミドモノヌクレオチド（ｎｍｎ）の使用、並びに対応する組成物 | |
| Oettmeier et al. | The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
| Chaney et al. | Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix | |
| Ramirez et al. | Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model |